Immuron Limited CEO to Present at Emerging Growth Conference

Immuron Limited announced that its CEO, Steven Lydeamore, will present at the Emerging Growth Conference on October 22, 2025. The presentation will be virtual, and Mr. Lydeamore will address the company's developments and take questions from attendees. Immuron is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. The company's flagship product, Travelan®, is an orally administered passive immunotherapy that reduces the risk of travelers' diarrhea. The presentation is part of Immuron's efforts to engage with investors and the broader financial community.